4.4 Review

Sarcopenia in pancreatic cancer: Effect on patient outcomes

期刊

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
卷 14, 期 12, 页码 2302-2312

出版社

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v14.i12.2302

关键词

Sarcopenia; Pancreatic cancer; Skeletal muscle; Computed tomography; Outcomes; Survival

资金

  1. National Research Foundation of Korea [NRF-2021 R1F1A1062255]

向作者/读者索取更多资源

Pancreatic cancer is a challenging disease with a poor prognosis, and malnutrition with muscle wasting is common among patients. Muscle wasting not only increases the risk of postoperative complications, but also decreases the recurrence-free and overall survival. In addition, muscle wasting can intensify chemotherapy-induced toxicities and worsen the quality of life and survival. Further studies are needed to confirm the prognostic role of muscle wasting and the effects of multimodal interventions in patients with pancreatic cancer.
Pancreatic cancer is a challenging disease with an increasing incidence and extremely poor prognosis. The clinical outcomes of pancreatic cancer depend on tumor biology, responses to treatments, and malnutrition or cachexia. Sarcopenia represents a severe catabolic condition defined by the age-related loss of muscle mass and strength and affects as much as 70% of malnourished pancreatic cancer patients. The lumbar skeletal muscle index, defined as the total abdominal muscle area at the L3 vertebral level adjusted by the square of the height, is widely used for assessing sarcopenia in patients with pancreatic cancer. Several studies have suggested that sarcopenia may be a risk factor for perioperative complications and decreased recurrence-free or overall survival in patients with pancreatic cancer undergoing surgery. Sarcopenia could also intensify chemotherapy-induced toxicities and worsen the quality of life and survival in the neoadjuvant or palliative chemotherapy setting. Sarcopenia, not only at the time of diagnosis but also during treatment, decreases survival in patients with pancreatic cancer. Theoretically, multimodal interventions may improve sarcopenia and clinical outcomes; however, no study has reported positive results. Further prospective studies are needed to confirm the prognostic role of sarcopenia and the effects of multimodal interventions in patients with pancreatic cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据